BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Open Access
- 11 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 10 (1), 1-12
- https://doi.org/10.1038/s41467-019-13530-6
Abstract
BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors, with highly disruptive BRCT domain mutations, have readily detectable BRCA1 protein expression, and are able to proliferate in the presence of PARPi. Peptide analyses reveal that chemo-resistant cancers contain residues encoded by BRCA1 intron 15. Mechanistically, cancers with BRCT domain mutations harbor BRCA1 gene breakpoints within or adjacent to Alu elements in intron 15; producing partial gene duplications, inversions and translocations, and terminating transcription prior to the mutation-containing BRCT domain. BRCA1 BRCT domain-deficient protein isoforms avoid mutation-induced proteasomal degradation, support homology-dependent DNA repair, and promote PARPi resistance. Taken together, Alu-mediated BRCA1 gene rearrangements are responsible for generating hypomorphic proteins, and may represent a biomarker of PARPi resistance.Funding Information
- Center for Strategic Scientific Initiatives, National Cancer Institute (P50 CA083638, R01CA214799)
- U.S. Department of Defense (OC130212)
This publication has 70 references indexed in Scilit:
- Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemiaNature, 2018
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerAnnals of Oncology, 2018
- Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer familiesCancer Medicine, 2018
- BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairingNature, 2017
- The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinCancer Research, 2016
- Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage SitesMolecular Cell, 2016
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional AssaysCancer Research, 2010
- Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domainExperimental Cell Research, 2004
- The BRCT Domain Is a Phospho-Protein Binding DomainScience, 2003